Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Delic Labs President and CSO Dr. Markus Roggen’s participation at the 11th annual MJBizCon in Las Vegas, Nevada on November 15, 2022.

MJBizScience Symposium
November 15, 2022
With over 1,400 exhibitors, 35,000 attendees and countless networking opportunities, MJBizCon is the world’s premier cannabis business conference and tradeshow. At this year’s conference, Dr. Markus Roggen will participate in MJBizScience Symposium’s panel discussion entitled, R&D As a Business Tool: Maximizing Revenue by Focusing on The Scientific Method. Alongside leading professionals within the cannabis industry, Roggen will highlight the foundational importance of research and development and explain how good science can help a company’s bottom line. For those in attendance at this year’s MJBizCon, the panel discussion is scheduled to begin at 11:20 a.m. on November 15, 2022, at the Westgate Resort in Las Vegas, Nevada.  To register for this year’s conference, please visit https://mjbizconference.com/

About Delic Labs

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.